Breaking News
0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

Avanos Medical (AVNS) Q2 Earnings and Revenues Top Estimates

By Zacks Investment ResearchStock MarketsAug 10, 2020 05:43AM ET
www.investing.com/analysis/avanos-medical-avns-q2-earnings-and-revenues-top-estimates-200533530
Avanos Medical (AVNS) Q2 Earnings and Revenues Top Estimates
By Zacks Investment Research   |  Aug 10, 2020 05:43AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 

Avanos Medical (NYSE:AVNS), Inc. AVNS reported adjusted earnings per share (EPS) of 13 cents in second-quarter 2020, against the Zacks Consensus Estimate of a loss of 8 cents. However, the bottom line declined 53.6% from the prior-year quarter.

Revenues of this Zacks Rank #3 (Hold) company were $163.7 million, which beat the Zacks Consensus Estimate by 10.2%. The top line, however, fell 4.9% on a year-over-year basis.

Q2 Segmental Analysis

Chronic Care

Net revenues at this segment of $120.2 million rose 17.5% year over year.

Pain Management

The segment reported net revenues of $43.5 million. The metric declined 37.8% on a year-over-year basis.

Margin Analysis

Adjusted gross profit was $91.2 million, down 11.8% from the prior-year quarter. Adjusted gross margin was 55.7% of net revenues, down 430 bps year over year.

Research and development expenses totaled $7.7 million, down 18.9% year over year. Selling, general and administrative expenses amounted to $76.9 million, down 18.8%.

Adjusted operating profit in the second quarter was $12.7 million, down 34.9% from the year-ago quarter.

Financial Update

As of Jun 30, 2020, cash and cash equivalents totaled $185 million, down 1.4% on a sequential basis.

Net cash provided in operating activities for the three months ended Jun 30, 2020, totaled $1.1 million, compared with net cash utilized in operating activities of $31.9 million in the prior-year quarter.

Guidance

In view of the rapidly evolving healthcare environment and the ongoing uncertainties related to the COVID-19 pandemic, the company has withdrawn its previously issued (provided on Feb 25, 2020) full-year 2020 outlook. At this point of time the company is unable to fully quantify the scope or duration of the impact of the pandemic on its financial results.

Summing Up

Avanos exited the second quarter on a strong note. The company continues to gain from its core segment — Chronic Care. NeoMed and Summit buyouts contributed 6% to the results. Further, rise in global demand in Respiratory Health owing to the pandemic positively impacted the performance.

However, the contraction in gross margin remains a worrisome. Also, the company’s Pain Management unit performed weakly. Further, the company witnessed lower volume in Acute Pain and Interventional Pain owing to fall in elective procedures. Moreover, being a pure-play MedTech company, it faces stiff competition from other industry players.

Key Picks

Some better-ranked stocks in the broader medical space are Thermo Fisher Scientific Inc (NYSE:TMO). TMO, PerkinElmer (NYSE:PKI), Inc. PKI and West Pharmaceutical Services (NYSE:WST), Inc. WST. While PerkinElmer sports a Zacks Rank of 1 (Strong Buy), both Thermo Fisher and West Pharmaceuticals carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

PerkinElmer reported second-quarter 2020 adjusted EPS of $1.57, surpassing the Zacks Consensus Estimate by 68.8%. Revenues of $811.7 million outpaced the consensus mark by 1.3%.

Thermo Fisher reported second-quarter 2020 adjusted EPS of $3.89, beating the Zacks Consensus Estimate by 45.7%. Revenues of $6.92 billion surpassed the consensus mark by 0.1%.

West Pharmaceuticals reported second-quarter 2020 adjusted EPS of $1.25, outpacing the Zacks Consensus Estimate of 91 cents. Revenues of $527.2 million surpassed the consensus estimate by 6.9%.

The Hottest Tech Mega-Trend of All

Last year, it generated $24 billion in global revenues. By 2020, it's predicted to blast through the roof to $77.6 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.

See Zacks' 3 Best Stocks to Play This Trend >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

PerkinElmer, Inc. (PKI): Free Stock Analysis Report

Thermo Fisher Scientific Inc. (TMO): Free Stock Analysis Report

West Pharmaceutical Services, Inc. (WST): Free Stock Analysis Report

AVANOS MEDICAL, INC. (AVNS): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research
Avanos Medical (AVNS) Q2 Earnings and Revenues Top Estimates
 

Related Articles

Tim Knight
Another Gap Play For CP By Tim Knight - Oct 21, 2021 2

Canadian Pacific (NYSE:CP) has come almost all the way back to a major price gap. Here’s the bigger picture. It’s doomtastic.

Avanos Medical (AVNS) Q2 Earnings and Revenues Top Estimates

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email